View Document Preview and Link Open Document File Size: 462,29 KB Share Result on Facebook
City Rockville / / Company HPC-Cs / / Country United States / / Event FDA Phase / / Facility Document Control Center / Rockville Pike / / IndustryTerm biological products / to biologic products / cord blood bank / unrelated allogeneic hematopoietic stem/progenitor cell products / individual applications / manufacturing / unlicensed placental/umbilical cord stem/progenitor cell products / human cellular and tissue-based products / placental/umbilical cord blood products / cellular and tissue-based products / manufacturing process / allogeneic products / / MedicalCondition Hurler Syndrome / Globoid Leukodystrophy / Krabbe Disease / communicable diseases / Hematological Malignancies / Primary immunodeficiency diseases / peroxisomal enzyme deficiency disorders / diseases / Beta thalassemia / relevant communicable disease / / Movie D. VII / D. V / / Organization office of Communication / Outreach and Development / Biological Response Modifiers Advisory Committee / Food and Drug Administration / U.S. Department of Health and Human Services Food and Drug Administration Center / FDA / Public Health Service / Control Center / Center for Biologics Evaluation and Research / / Person Cord Blood Hematopoietic Stem / Cord Blood Intended / / / Position Representative / General / / Product HPC-Cs / New Drug / / ProvinceOrState Maryland / Indiana / / RadioStation 2 What / / Technology transplantation / / URL http / SocialTag 
Guidance for Industry Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications